Upfront clinches $4.3m to advance stroke test in UK, US and elsewhere
Summary
The company received non-dilutive funding from SBRI Healthcare as part of the round.LVOne is a proprietary fingerstick blood test designed to diagnose strokes rapidly and accurately anywhere. Upfront says the test has the potential to significantly improve patient outcomes by enabling faster treatment decisions and reducing the risk of long-term disability.It says the financial haul will not only initiate commercialisation of LVOne in the UK and Europe but also support regulatory approval precesses in the US and expand Upronts R & D capabilities.CEO, Gonzalo Ladreda said: "This funding round is a significant milestone for Upfront. We are grateful for the support of our investors and partners, and we look forward to continuing our mission to improve stroke diagnosis and treatment. "Chair, Dr Tito Bacarese added: "The perseverance and innovative spirit demonstrated by Upfronts team have been instrumental in securing this funding. This achievement is a testament to their unwavering dedication to revolutionising the diagnostics landscape by providing elegant solutions for complex conditions.We are grateful to have the backing of a prestigious group like Phoenix Investments, whose support will enable Upfront to impact thousands of lives.
Funding
Review available funding amount, funding date, investors, and linked company information related to Upfront clinches $4.3m to advance stroke test in UK, US and elsewhere in the interactive ISVWorld profile.